As the effectiveness of social networking in tech transfer has become increasingly apparent, more and more TTO leaders have engaged with a number of social networks to enhance their marketing efforts. But while many have enjoyed some level of success from their endeavors, it is unlikely that few, if any, can match the nearly 40,000 LinkedIn connections and impressive business achievements achieved by Tamir Huberman, MSc, BSc, vice president of business development for computer science and IT director at Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
CNN's Oren Liebermann visits a company that will help Rio monitor its bank of surveillance cameras and help authorities keep track of whats happening at street level.
Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that RenewSense was selected to enter Brainnovation, Israel's Brain Technologies accelerator. RenewSenses, based on research from the lab of Professor Amir Amedi, from the Department of Medical Neurobiology at the Hebrew University of Jerusalem and the Edmond & Lily Safra Center for Brain Science, develops devices that can aid the blind and visually-disabled to navigate using other senses like sound and touch.
Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA), a pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced today that it entered into a binding memorandum of understandings with Yissum, the technology transfer company of the Hebrew University of Jerusalem, to receive an exclusive, worldwide license to use a patent-protected formulation for nasal administration of cannabinoid substances. The technology, developed by Prof. Elka Touitou from the Institute of Drug Research at the Hebrew University of Jerusalem, facilitates administration and effective absorption of the active ingredient THC nasally.
Yissum announced that it has signed a non-exclusive worldwide licensing agreement and a consulting agreement with Lightricks for the development and commercialization of an imaging technology that improves digital image processing. The technology, invented by Prof. Raanan Fattal from the School of Computer Science and Engineering at theHebrew University of Jerusalem, is called "Edge Avoiding Wavelets" and it enables better and faster detail enhancement and preserves edges when sharpening digital images.
Yissum, the technology transfer company of the Hebrew University of Jerusalem, has over 9,300 patents and 110 spin-offs to its name. The 52-year old company–the third oldest in the world of its kind–works closely with researchers at the university and connects them to commercial partners such as Intel and Google. It also creates an average of 10 new companies per annum, with some like Mobileye valued at over $9 billion today.
According to Yissum’s vice-president of marketing Dana Gavish-Fridman, Yissum-commercialized products generate over $2 billion in annual sales, with the company receiving a healthy three to five percent in royalties. Other sources of income include equity and investments by industry players.
HIL is betting that Nanoblaz’s nanotechnology could help them find cancer treatment
Non-invasive diagnostic test realizes the potential of circulating DNA for detection of multiple diseases
The novel technology was developed by Yinon Ben-Neriah, MD, PhD, Blumenthal Professor of Cancer Research, Lautenberg Center for Immunology, Hebrew University-Hadassah Medical School, with generous support by AMRF (The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation). Dr. Ben-Neriah and his team showed that inhibition of the clinically validated enzyme CKI-alpha induces several tumor suppressor pathways, including a new type of DNA damage response and p53 activation. This provides a novel approach to treat a wide range of cancers, in particular selective types of hematological malignancies.
Imagine nanoparticles that can carry a cancer drug directly to malignant cells and release it slowly for optimal effect.
Imagine a “green” method to transform plastic waste into valuable industrial products.
These inventions were among those highlighted at Innovations in Advanced Materials, a recent conference showcasing breakthrough nanotechnologies from Hebrew University of Jerusalem scientists for use in everything from sensors and coating materials to electronics and 3D printing.
Hebrew University's liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Yissum, the technology transfer company of the Hebrew University, has recently filed two provisional patent applications covering the promising Liver-on-Chip technology, that will be the basis of a new company to be established together with Prof. Yaakov Nahmias. This New Company will provide diagnostic and prognostic analysis for Pharmaceutical and Cosmetics companies to help define drug safety and screen out idiosyncratic drug toxicity.
Israeli researchers develop method to diagnose diabetes, multiple sclerosis, pancreatic cancer, pancreatitis and brain damage from one blood test.
"In the long run, we envision a new type of blood test aimed at the sensitive detection of tissue damage, even without [prior] suspicion of disease in a specific organ. We believe that such a tool will have broad utility in diagnostic medicine and in the study of human biology,” said Prof. Benjamin Glaser, head of endocrinology at Hadassah Medical Center and another lead author of the study along with Prof. Yuval Dor, a developmental biologist at the Hebrew University of Jerusalem."
Eight companies were founded in 2015 through Yissum based on research at the Hebrew University’s Center for Nanoscience and Nanotechnology.
Shades and curtains that can light up a room or darken a window, making them as transparent or as opaque as desired; monitoring of physiological parameters such as stress, fatigue, pain, alcohol influence, drug use, and other factors using electromagnetic emissions from sweat ducts; 3D printers that can print circuit boards and sensors; threads that are stronger than spider webs; and dozens of new nano-technology innovations and inventions.
It’s all part of the brave new world of nano-materials technology, in which nano-tech is employed to develop fibers, metals, and other materials to do the above and much more. In fact, all of those products and technologies were designed by Israeli high-tech firms Qlight, Neteera, Nano-Dimension, and Seevix, respectively.
What all those companies have in common is that they are graduates of technology developed at Hebrew University and promoted by Yissum, Hebrew U’s tech transfer company – and on March 29th, Yissum and Hebrew University will be sponsoring its first-ever Advanced Materials Conference.
JVP to Operate Jerusalem-based Startup Incubator for 8 Years in Partnership with Motorola Solutions, Reliance Industries and Yissum, the Research Development Company of the Hebrew University of Jerusalem
Yissum Research Development Company of the Hebrew University of Jerusalem, the technology-transfer company of the Hebrew University, announced today the formation of Neteera Technologies, developer of remote sensing technology of various human biological indicators. Neteera Technologies has completed its first round of funding, raising $2.0 million from private investors.
Scientists from The Hebrew University of Jerusalem, Columbia University Medical Center and The New York Stem Cell Foundation Research Institute have succeeded in generating a new type of embryonic stem cell that carries a single copy of the human genome, instead of the two copies typically found in normal stem cells.
Melodea is pioneering the development of an economically viable industrial process for the extraction of Nano Crystalline Cellulose (known as NCC or CNC) from the sludge of the paper industry. It developes unique technologies to assemble the NCC into ecologically friendly foams as well as enhancement of strength and other properties of materials such as: bio-packaging, paper, acrylic glues and paints.
Exelon, for example, is a treatment for Alzheimer’s that helps patients cope with the disease and remain independent longer. Marketed by Novartis, the drug is based on research that was conducted at Hebrew University. Doxil, sold by Johnson and Johnson, effectively helps treat numerous cancers, and it, too, was developed at Hebrew U, along with researchers at Hadassah Medical Center. And, of course, there’s multiple sclerosis drug Copaxone, developed at the Weizmann Institute and marketed by Israel’s own Teva Pharmaceuticals.